StockNews.com Downgrades aTyr Pharma (NASDAQ:LIFE) to Sell

aTyr Pharma (NASDAQ:LIFEGet Rating) was downgraded by investment analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Friday.

LIFE has been the topic of several other research reports. Piper Sandler lifted their price target on shares of aTyr Pharma from $11.00 to $14.00 and gave the stock an “overweight” rating in a research note on Monday, August 15th. HC Wainwright raised their price objective on shares of aTyr Pharma from $11.00 to $35.00 and gave the stock a “buy” rating in a report on Thursday, July 21st.

aTyr Pharma Price Performance

aTyr Pharma stock opened at $2.49 on Friday. aTyr Pharma has a 12-month low of $2.22 and a 12-month high of $8.90. The company has a market capitalization of $71.29 million, a price-to-earnings ratio of -1.51 and a beta of 1.31. The firm’s fifty day moving average price is $2.81 and its 200 day moving average price is $3.10.

aTyr Pharma (NASDAQ:LIFEGet Rating) last released its quarterly earnings results on Monday, August 15th. The biotechnology company reported ($0.44) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.01). During the same period in the previous year, the firm earned ($0.64) EPS. Analysts forecast that aTyr Pharma will post -1.81 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in LIFE. Tikvah Management LLC grew its holdings in aTyr Pharma by 10.2% during the 1st quarter. Tikvah Management LLC now owns 1,350,833 shares of the biotechnology company’s stock worth $7,227,000 after acquiring an additional 125,000 shares in the last quarter. Alyeska Investment Group L.P. boosted its holdings in shares of aTyr Pharma by 12.7% in the 1st quarter. Alyeska Investment Group L.P. now owns 760,798 shares of the biotechnology company’s stock valued at $4,070,000 after buying an additional 85,823 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of aTyr Pharma by 36.1% in the 2nd quarter. Renaissance Technologies LLC now owns 150,825 shares of the biotechnology company’s stock valued at $427,000 after buying an additional 39,970 shares during the period. FMR LLC boosted its holdings in shares of aTyr Pharma by 0.9% in the 2nd quarter. FMR LLC now owns 4,208,437 shares of the biotechnology company’s stock valued at $11,910,000 after buying an additional 39,068 shares during the period. Finally, State Street Corp boosted its holdings in shares of aTyr Pharma by 48.1% in the 1st quarter. State Street Corp now owns 82,908 shares of the biotechnology company’s stock valued at $444,000 after buying an additional 26,909 shares during the period. 65.58% of the stock is owned by institutional investors and hedge funds.

About aTyr Pharma

(Get Rating)

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.

Further Reading

Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.